What is Antibody-drug Conjugates Market Scope?
Antibody-drug Conjugates or ADCs are extremely targeted biopharmaceutical medications that combine monoclonal antibodies specific to surface antigens present on specific tumor cells with extremely potent anti-cancer agents connected via a chemical linker. Antibody-drug Conjugates (ADC) are empowered antibodies (MAbs) designed to harness the targeting ability of organism antibodies by linking them to cell-killing agents. Antibody-drug conjugates comprise 3 components, chiefly a particular antibody for binding, a cytotoxic agent designed to kill target cancer cells, and a chemical linker for attaching the cytotoxic agent to the protein. The combined impact of targeting specific varieties of cells and therefore the killing ability of cytotoxic drugs build this drug conjugate the perfect one for the treatment of varied cancers. The success of this technology has become possible solely with increasing technological advancements. The potential of a medication embedded within the antibody-drug conjugate is augmented by 100–1000 fold over the potential of the medication once it acts alone.
The Antibody-drug Conjugates market study is being classified by Type (Monoclonal Antibody, Potent Cytotoxic Agent, Linker and Others), by Application (Leukemia, Glioblastoma, Lymphoma and Others) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Players from United States will contribute to the maximum growth of Global Antibody-drug Conjugates market throughout the predicted period.
Seattle Genetics (United States), ImmunoGen, Inc. (United States), Roche Holding AG (Switzerland), Genentech (United States), Concortis Biotherapeutics (United States), Agensys, Inc. (United States), Antikor (United Kingdom), Immunomedics (United States), Pfizer Inc. (United States), Celldex Therapeutics (United States), Millennium Pharmaceuticals (United States), AbbVie Inc. (United States), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan) and Progenics Pharmaceuticals (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Oxford BioTherapeutics (United States), Mersana Therapeutics (United States), Synthon (United States) and Heidelberg Pharma (Germany).
Analyst at AMA have segmented the market study of Global Antibody-drug Conjugates market by Type, Application and Region.
On the basis of geography, the market of Antibody-drug Conjugates has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Influencers and their development strategies
On 04th January 2020, Legochem Biosciences and Iksuda entered a licensing agreement for the Drug Conjugate Program. Under this agreement, Iksuda would make a payment of USD 5 Million and LCB is eligible to receive development. and In March 2019, AstraZeneca entered into a global development and commercialization collaboration agreement with Daiichi Sankyo Company for the proprietary antibody-drug conjugate trastuzumab deruxtecan (DS-8201).
On 18th May 2020, FDA granted the Breakthrough Therapy Status for AstraZeneca’s Enhertu for the treatment of the patients who are HER2 positive.
Influencing Market Trend
- Increase in the Adoption of the Drug
- A Rise in The Recommendation of Medical Experts to Consume the Drug to Overcome Cancer
- Increase in The Obese Population
- Rising Cases of Cancer
- Growing Ageing Population
- Increasing Research Activities on Antibody Therapies
- More Research on Advanced Drug Discoveries and Oncology Diseases
- High Capital Investment Required for Manufacturing
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Providers of Antibody-drug Conjugates, Venture Capitalists and Private Equity Firms and End-Use Industry
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.